CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rua Life Sciences PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rua Life Sciences PLC
2 Drummond Crescent, Irvine
Phone: +44 1294317073p:+44 1294317073 AYRSHIRE, KA11 5AN  United Kingdom Ticker: RUARUA

Business Summary
RUA Life Sciences plc is a United Kingdom-based holding company. The Company’s principal activities comprise of exploiting the value of its intellectual property (IP) and know-how, medical device contract manufacturing and development of cardiovascular devices. The Company operates through four businesses, which include RUA Medical, RUA Biomaterials, RUA Vascular and RUA Structural Heart. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its class seven and eight cleanroom suites. RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-Eon and ECSil. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20233/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board William D.Brown 59 6/8/2018 10/21/2011
Group Chief Financial Officer, Executive Director Lachlan A.Smith 41 3/31/2022 3/31/2022
Group Managing Director CarolineStretton 1/29/2024 1/18/2021
4 additional Officers and Directors records available in full report.

Business Names
Business Name
AOR
AorTech International plc
RUA

General Information
Number of Employees: 40 (As of 3/31/2023)
Outstanding Shares: 62,060,272 (As of 12/19/2023)
Shareholders: 8,200
Stock Exchange: LON
Fax Number: +44 1932251113


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024